Group 1 - Kangfang Biotech (09926) shares rose over 4%, reaching a new high of 173.8 HKD, with a trading volume of 1.212 billion HKD [1] - The 2025 World Lung Cancer Conference (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where Kangfang's partner Summit Therapeutics will present the results of the HARMONi study, a pivotal Phase III clinical trial for the PD-1/VEGF bispecific antibody drug, Ivoris [1] Group 2 - UBS has added Kangfang Biotech to its list of major recommended stocks in the Asia-Pacific region, citing the overseas potential of its main asset, Ivoris, which is not fully reflected in the stock price [2] - The firm believes that reports of potential collaborations with multinational companies and the upcoming HARMONi study results will act as positive catalysts for the stock price [2] - UBS raised its peak sales forecast for Ivoris from 14.6 billion USD to 16.3 billion USD and for another key asset, Kantan, from 2.2 billion USD to 3.4 billion USD, increasing the target price from 197.5 HKD to 224.3 HKD with a "Buy" rating [2]

Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.5% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.3% [1] - The China Securities Biotechnology Theme Index and the China Securities Innovative Drug Industry Index both saw an increase of 0.7% and 0.5% respectively [1] - The CSI 300 Pharmaceutical and Health Index grew by 0.6% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 18 million units, reaching a record high of 1.26 billion yuan [1] Index Details - The Biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading A-share biotechnology companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4] - The rolling price-to-earnings (P/E) ratio for the Biotechnology Theme Index is 55.3 times, with a valuation percentile of 0.7% [5] - The Pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices [6][7] - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 30.7 times, with a valuation percentile of 45.7% [7] ETF Characteristics - The Hang Seng Innovative Drug ETF is the only ETF tracking the innovative drug index, with a low management fee of 0.15% per year and a custody fee of 0.05% per year [9]

Core Viewpoint - The establishment of Shennongjia Zhongyue Oasis Biotechnology Co., Ltd. indicates a growing interest in the agricultural and biotechnology sectors, with a focus on various agricultural products and services [1] Company Summary - Shennongjia Zhongyue Oasis Biotechnology Co., Ltd. was recently founded with a registered capital of 5 million RMB [1] - The legal representative of the company is Han Daiju [1] - The company is primarily owned by Chengdu Douqi Culture Communication Co., Ltd. (80%) and Sichuan New Oasis Electric Power Sales Co., Ltd. (20%) [1] Business Scope - The company’s business activities include technology services, development, consulting, and transfer, as well as the production, sales, processing, transportation, and storage of agricultural products [1] - It also engages in the wholesale and retail of edible agricultural products, health food sales, and the cultivation of edible fungi and traditional Chinese medicine [1] - The company is involved in various sales activities, including daily necessities, cosmetics, and jewelry, along with information technology and IoT services [1] - Certain activities require licenses, such as edible fungus seed operations and beverage production [1] Industry Context - The company operates within the manufacturing industry, specifically in the beverage manufacturing sector [1] - The registered address is located in Shennongjia Forest District, Hubei Province [1] - The business is set to operate until at least August 14, 2025, with no fixed end date [1]

Core Viewpoint - Kweichow Moutai Group is focusing on integrating biotechnology and digital technology, aiming to enhance talent acquisition and development in these fields to drive innovation and application expansion [1] Group 1: Talent Development - The company plans to introduce and cultivate talents in information digitization and biomanufacturing [1] - Emphasis on deep integration of "production, education, research, and application" to promote the transformation of innovative achievements [1] Group 2: International Market Strategy - Kweichow Moutai aims to adopt a more open approach to international market operations [1] - The company is focused on enhancing its brand's international expression and continuously attracting and training international marketing talents [1] - There is an active exploration of overseas market pathways to expand the overseas consumer base and steadily advance its international strategy [1]

Core Viewpoint - The A-share financing balance has surpassed 20 trillion yuan, reaching a nearly ten-year high, indicating strong market interest in the brokerage sector, particularly in broker ETFs, which have seen significant inflows and nearly doubled in size over the past eight weeks [1][4]. Short-term Dynamics - Market risk appetite has improved, with the Shanghai Composite Index and the securities sector showing year-to-date gains of 8.82% and 2.95%, respectively, suggesting potential for further gains in the brokerage sector [4]. - As of August 11, the total financing balance in the A-share market reached 20.05689 trillion yuan, marking a significant increase and reflecting heightened market sentiment [4]. - The current A/H share premium for brokerage stocks is low, with Hong Kong's securities index up 49.92% year-to-date, while A-share brokerage stocks have only increased by an average of 4.63% [4]. - Institutional investors are underweight in the brokerage sector, with active equity funds allocating only 0.64% to brokerages, significantly below the five-year high of 2.0%, indicating potential for increased capital inflows [5]. Mid-term Support - The brokerage sector's net profit for Q1 2025 grew by 83% year-on-year, driven by strong performance in investment and brokerage businesses [8]. - A significant number of brokerages have issued positive mid-year profit forecasts, with many expecting substantial year-on-year growth, which could act as a catalyst for the sector's performance [8]. - The trend of mergers and acquisitions within the brokerage industry is intensifying, with several notable transactions indicating a focus on internal consolidation [8]. Long-term Trends - There is a growing interest in Chinese assets, with various investment themes attracting capital in both A-shares and Hong Kong stocks [11]. - The internationalization of the renminbi is providing new momentum for brokerage firms, with a notable increase in cross-border transactions and services [11]. - The brokerage sector is positioned at a critical juncture for value reassessment and upward trends, with low-cost investment tools like broker ETFs offering efficient market access for investors [12].

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-065 华润双鹤药业股份有限公司 关于设立华润双鹤产业基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： ? 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润 双鹤"或"公司")拟投资设立华润双鹤生物医药产业基金(呼和浩特) 投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华 润双鹤产业基金"或"该基金")，基金目标募集规模为 5 亿元人民 币，公司及全资子公司双鹤(北京)生物技术有限公司(以下简称"双鹤 生物")拟以自有资金出资不超过 8,700 万元人民币，占基金总出资额 的比例不超过 17.40%。 ? 本次交易构成关联交易，不构成重大资产重组。 ? 本次交易金额超过 3,000 万元，未超过公司 2024 年度经审计 净资产的 5%，已经董事会审议批准，无需提交股东会审议。 ? 过去 12 个月内，除日常关联交易及本次交易外，公司拟以自 有资金 4,000 万元人民币与华润医药投资有限公司等 11 ...

Core Viewpoint - Overseas long-term funds are intensively conducting due diligence on Chinese asset managers, indicating a renewed interest in China's investment opportunities after a three-year hiatus [1][2]. Group 1: Due Diligence Activities - Numerous Chinese asset managers, including domestic and overseas Chinese investment institutions, have undergone due diligence from overseas long-term funds in the past quarter [3]. - APS, a Singapore asset management firm, has seen significant capital inflow from both domestic and Singaporean investors, including family offices and high-net-worth individuals [3]. - Overseas institutions are particularly interested in the historical holdings and trading decisions of asset managers to understand their investment style and sources of returns [3][4]. Group 2: Investment Process and Preferences - Establishing a long-term partnership requires asset managers to have a scalable and repeatable investment process; inconsistency in performance can lead to skepticism from overseas institutions [4]. - Overseas investors are focusing on seven key areas during due diligence, including investment management systems, risk management capabilities, organizational structure, alignment of interests, fee structures, macroeconomic outlook, and geopolitical risk assessments [5]. - There is a notable interest from overseas family offices and funds of funds (FOFs) in absolute return-oriented investment strategies and products [4][5]. Group 3: Market Sentiment and Future Outlook - Despite some overseas institutions showing interest, pension funds and sovereign wealth funds have not yet made significant adjustments to their allocations [6]. - The return of North American pension funds to China is anticipated around 2026, contingent on favorable market conditions and performance [7][9]. - Global funds are currently underweight in China, with a 11% allocation level, significantly lower than the benchmark, indicating a cautious approach due to past market volatility and economic uncertainties [8][9]. Group 4: Investment Opportunities in Technology - There is a shift in focus towards hard technology sectors, with a particular emphasis on the semiconductor industry, which is seen as a key area for China's future growth [12][14]. - Companies like SMIC are highlighted for their potential, with expectations of significant improvements in return on equity (ROE) over the next few years [12][13]. - The changing landscape in China, including reduced importance of real estate and shifts in industrial policy, presents new opportunities for global investors to engage with emerging Chinese enterprises [14].

Core Viewpoint - The Vietnamese Communist Party emphasizes the crucial role of intellectuals, scientists, and artists in national development and stability, especially in the context of rapid global changes and technological advancements [1][2]. Group 1: Importance of Intellectuals and Scientists - The Vietnamese leadership acknowledges the significant contributions of intellectuals, scientists, and artists to the nation's historical development [1]. - The current era is characterized by knowledge as a key resource for development, necessitating the active participation of these groups to adapt to changes brought by the Fourth Industrial Revolution and digital transformation [1]. Group 2: Focus Areas for Development - Intellectuals, scientists, and artists are encouraged to focus on key areas such as technology, education, healthcare, high-tech agriculture, digital economy, digital society, green energy transition, and circular economy to support sustainable national development [2]. Group 3: Ethical Standards and Responsibilities - There is a strong emphasis on the need for these professionals to uphold ethical standards, integrity, and social responsibility, particularly in an era where misinformation and artificial intelligence can create false content [2]. - The qualities of integrity and honesty are highlighted as essential for defending truth and building a healthy society [2]. Group 4: Support from the Government - The Vietnamese government is committed to creating conditions for intellectuals, scientists, and artists to fully utilize their talents and creativity for national development [2]. - There is confidence that these groups will continue to lead and inspire the nation towards a prosperous future [2].

本报（chinatimes.net.cn）记者王兆寰 北京报道 "嗡嗡……嗡嗡……"孔芳芳的手机持续震动着，她有点看不过来短消息了。 7月23日，随着沪指突破3600点，券商营业部的客户们开始了更多咨询。"指数虽然涨到3600点了，但是 自己的持仓市值还停留在3000点，想要寻求专业的帮助。"一个客户在不停问她。 孔芳芳是国元证券北京东直门外大街营业部营销总监。按她自己的话说，近期工作"变忙了"。 7月11日，在沪指站上3500点后，她给大约800名客户发了信息，并提示客户行情在不断地向好，也给出 了原因：包括国家政策的预期在加强，提振消费、发展新质生产力的速度在加快等等。"其实就是提醒 客户，现阶段市场可以积极地看多，不适宜看空。" "信息发出之后，收到的回复并不多，可能大部分人看到也就看到了，要么不相信，要么不在意。只有 小部分仓位轻的股民会来探讨一下市场。"孔芳芳有些无奈。不过，在大盘站上3600以后，她再给这部 分人发信息时，回复的人明显多了。 流火的7月，A股经历了完美"大翻身"，三大指数迭创新高，沪指连闯3500和3600整数关卡，热点板块 层出不穷，成交量不断变大。A股市场新开户数达196万户， ...

金融界8月5日消息，上证指数高开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1886.25点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨22.20%，近三个月上涨54.39%，年至今上 涨108.66%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 从指数持仓来看，中证港股通生物科技主题指数十大权重分别为：百济神州（13.23%）、信达生物 （12.79%）、药明生物（9.82%）、康方生物（8.87%）、中国生物制药（6.39%）、石药集团 （6.11%）、三生制药（4.69%）、翰森制药（3.27%）、药明康德（3.03%）、科伦博泰生物-B （2.67%）。 本文源自：金融界 作者：行情君 从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通生物科技主题指数持仓样本的行业来看，化学药占比40.03%、生物药品占比38.7 ...